In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Defining quality tolerance limits and key risk indicators that detect risks in a timely manner
In this article, Gillian Pilbrow, along with multiple other SMEs from other organisations, discuss effective risk control through the earliest possible risk detection practices.
-
-
ICON: Where quality meets quantity
In this article, featuring commentary from CEO Steve Cutler, ICON’s key business moves in the last year are highlighted.
-
Business & Finance CEO 100 index 2022
Steve Cutler is featured in the first instalment of the annual CEO 100 index which recognises leading chief executives in Ireland.
-
PwC interview: Dr Steve Cutler, CEO of ICON plc
Participating in PWC's CEO Survey 2022, Dr Steve Cutler discusses the role of M&A in growth strategy.
-
How this top CEO helped Pfizer turbocharge the covid-19 vaccine
Steve Cutler discusses ICON's covid-19 efforts, the importance of building a good team, and more in this interview with Investor's Business Daily.
-
3 Irish finance experts on the best ways to lead your business
Emer Lyons, VP of Finance, shares her learnings and top takeaways for navigating the post-COVID economy.
-
How healthcare can develop through digital innovation
Gerard Quinn and Barbara Skerritt offer their insights into the rapid acceleration of digital innovation in clinical research in the past two years.
-
ICON says Russia’s invasion may disrupt clinical trials underway in Ukraine
This article features commentary from Steve Cutler on the impact of the war in Ukraine on clinical trials in the region.
-
Continuing the fight against antimicrobial resistance
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, offers her insights on the necessary actions to combat the threat of AMR.
This article is taken from European Biopharmaceutical Review April 2022, pages 8-10. Samedan Ltd.
